img

Global Tumor Necrosis Factor Receptor Superfamily Member 18 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Tumor Necrosis Factor Receptor Superfamily Member 18 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Tumor Necrosis Factor Receptor Superfamily Member 18 market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Tumor Necrosis Factor Receptor Superfamily Member 18 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Tumor Necrosis Factor Receptor Superfamily Member 18 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 18 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18 include Ablynx NV, Amgen Inc, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, Merck & Co Inc and Novartis AG, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Tumor Necrosis Factor Receptor Superfamily Member 18, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Tumor Necrosis Factor Receptor Superfamily Member 18 by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Tumor Necrosis Factor Receptor Superfamily Member 18 market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Tumor Necrosis Factor Receptor Superfamily Member 18 market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Ablynx NV
Amgen Inc
Apogenix GmbH
Bristol-Myers Squibb Company
Five Prime Therapeutics Inc
Incyte Corp
MedImmune LLC
Merck & Co Inc
Novartis AG
OncoMed Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
By Type
AMG-228
BMS-986156
FPA-154
GWN-323
INCAGN-1876
Others
By Application
Melanoma
Non-Small Cell Lung Cancer
Gastric Cancer
Blood Cancer
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Tumor Necrosis Factor Receptor Superfamily Member 18 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 18 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Necrosis Factor Receptor Superfamily Member 18 sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Definition
1.2 Market by Type
1.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 AMG-228
1.2.3 BMS-986156
1.2.4 FPA-154
1.2.5 GWN-323
1.2.6 INCAGN-1876
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Melanoma
1.3.3 Non-Small Cell Lung Cancer
1.3.4 Gastric Cancer
1.3.5 Blood Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales
2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Estimates and Forecasts 2018-2034
2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region
2.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2018-2024)
2.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2024-2034)
2.4 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region
2.6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region (2018-2024)
2.6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Manufacturers
3.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Receptor Superfamily Member 18 Sales in 2022
3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Manufacturers
3.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Manufacturers (2018-2024)
3.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue in 2022
3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price by Manufacturers
3.4 Global Key Players of Tumor Necrosis Factor Receptor Superfamily Member 18, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Product Offered and Application
3.8 Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type
4.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type
4.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Historical Revenue by Type (2018-2024)
4.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Forecasted Revenue by Type (2024-2034)
4.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
4.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Type
4.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Type (2018-2024)
4.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application
5.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application
5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Historical Revenue by Application (2018-2024)
5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Forecasted Revenue by Application (2024-2034)
5.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Application
5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Application (2018-2024)
5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price Forecast by Application (2024-2034)
6 North America
6.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Company
6.1.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024)
6.1.2 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024)
6.2 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Type
6.2.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2034)
6.2.2 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2034)
6.3 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Application
6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2034)
6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2034)
6.4 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Country
6.4.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2034)
6.4.3 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Company
7.1.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024)
7.1.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024)
7.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Type
7.2.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2034)
7.2.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2034)
7.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Application
7.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2034)
7.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2034)
7.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Country
7.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2034)
7.4.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Company
8.1.1 China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024)
8.1.2 China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024)
8.2 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Type
8.2.1 China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2034)
8.2.2 China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2034)
8.3 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Application
8.3.1 China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2034)
8.3.2 China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Company
9.1.1 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024)
9.1.2 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024)
9.2 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Type
9.2.1 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2034)
9.2.2 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2034)
9.3 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Application
9.3.1 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2034)
9.3.2 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2034)
9.4 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Region
9.4.1 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2018-2034)
9.4.3 APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Company
10.1.1 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Type
10.2.1 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Application
10.3.1 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size by Country
10.4.1 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Ablynx NV
11.1.1 Ablynx NV Company Information
11.1.2 Ablynx NV Overview
11.1.3 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.1.5 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.1.6 Ablynx NV Recent Developments
11.2 Amgen Inc
11.2.1 Amgen Inc Company Information
11.2.2 Amgen Inc Overview
11.2.3 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.2.5 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.2.6 Amgen Inc Recent Developments
11.3 Apogenix GmbH
11.3.1 Apogenix GmbH Company Information
11.3.2 Apogenix GmbH Overview
11.3.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.3.5 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.3.6 Apogenix GmbH Recent Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Information
11.4.2 Bristol-Myers Squibb Company Overview
11.4.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.4.5 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.4.6 Bristol-Myers Squibb Company Recent Developments
11.5 Five Prime Therapeutics Inc
11.5.1 Five Prime Therapeutics Inc Company Information
11.5.2 Five Prime Therapeutics Inc Overview
11.5.3 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.5.5 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.5.6 Five Prime Therapeutics Inc Recent Developments
11.6 Incyte Corp
11.6.1 Incyte Corp Company Information
11.6.2 Incyte Corp Overview
11.6.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.6.5 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.6.6 Incyte Corp Recent Developments
11.7 MedImmune LLC
11.7.1 MedImmune LLC Company Information
11.7.2 MedImmune LLC Overview
11.7.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.7.5 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.7.6 MedImmune LLC Recent Developments
11.8 Merck & Co Inc
11.8.1 Merck & Co Inc Company Information
11.8.2 Merck & Co Inc Overview
11.8.3 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.8.5 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.8.6 Merck & Co Inc Recent Developments
11.9 Novartis AG
11.9.1 Novartis AG Company Information
11.9.2 Novartis AG Overview
11.9.3 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.9.5 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.9.6 Novartis AG Recent Developments
11.10 OncoMed Pharmaceuticals Inc
11.10.1 OncoMed Pharmaceuticals Inc Company Information
11.10.2 OncoMed Pharmaceuticals Inc Overview
11.10.3 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.10.5 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
11.10.6 OncoMed Pharmaceuticals Inc Recent Developments
11.11 Regeneron Pharmaceuticals Inc
11.11.1 Regeneron Pharmaceuticals Inc Company Information
11.11.2 Regeneron Pharmaceuticals Inc Overview
11.11.3 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Products and Services
11.11.5 Regeneron Pharmaceuticals Inc Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Value Chain Analysis
12.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Tumor Necrosis Factor Receptor Superfamily Member 18 Production Mode & Process
12.4 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Marketing
12.4.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Channels
12.4.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Distributors
12.5 Tumor Necrosis Factor Receptor Superfamily Member 18 Customers
13 Market Dynamics
13.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Industry Trends
13.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Drivers
13.3 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Challenges
13.4 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of AMG-228
Table 3. Major Manufacturers of BMS-986156
Table 4. Major Manufacturers of FPA-154
Table 5. Major Manufacturers of GWN-323
Table 6. Major Manufacturers of INCAGN-1876
Table 7. Major Manufacturers of Others
Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Region (2018-2024)
Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Region (2024-2034)
Table 14. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 15. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Region (2018-2024) & (K Pcs)
Table 16. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share by Region (2018-2024)
Table 17. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share by Region (2024-2034)
Table 19. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 20. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Manufacturers (2018-2024)
Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Manufacturers (2018-2024)
Table 23. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Manufacturers 2018-2024 (USD/Pcs)
Table 24. Global Key Players of Tumor Necrosis Factor Receptor Superfamily Member 18, Industry Ranking, 2021 VS 2022
Table 25. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Tumor Necrosis Factor Receptor Superfamily Member 18 by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Receptor Superfamily Member 18 as of 2022)
Table 27. Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Product Offered and Application
Table 29. Global Key Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 18, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 32. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Type (2018-2024)
Table 34. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Type (2024-2034)
Table 35. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 36. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Type (2018-2024)
Table 38. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Type (2024-2034)
Table 39. Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Type (2018-2024) & (USD/Pcs)
Table 40. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 42. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Application (2018-2024)
Table 44. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Application (2024-2034)
Table 45. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 46. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Application (2018-2024)
Table 48. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Application (2024-2034)
Table 49. Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Application (2018-2024) & (USD/Pcs)
Table 50. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024) & (US$ Million)
Table 52. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024) & (K Pcs)
Table 53. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 54. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 56. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 58. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 60. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 62. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2024) & (US$ Million)
Table 63. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2024) & (K Pcs)
Table 65. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024) & (K Pcs)
Table 67. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024) & (US$ Million)
Table 68. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 69. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 71. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 73. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 75. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 77. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2024) & (US$ Million)
Table 78. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2024) & (K Pcs)
Table 80. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024) & (K Pcs)
Table 82. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024) & (US$ Million)
Table 83. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 84. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 86. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 88. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 90. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024) & (K Pcs)
Table 92. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024) & (US$ Million)
Table 93. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 94. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 96. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 98. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 100. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 102. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2018-2024) & (US$ Million)
Table 103. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region (2018-2024) & (K Pcs)
Table 105. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Company (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Company (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2018-2024) & (K Pcs)
Table 109. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2018-2024) & (K Pcs)
Table 113. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2018-2024) & (US$ Million)
Table 118. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2018-2024) & (K Pcs)
Table 120. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. Ablynx NV Company Information
Table 122. Ablynx NV Description and Overview
Table 123. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 125. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 126. Ablynx NV Recent Developments
Table 127. Amgen Inc Company Information
Table 128. Amgen Inc Description and Overview
Table 129. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 130. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 131. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 132. Amgen Inc Recent Developments
Table 133. Apogenix GmbH Company Information
Table 134. Apogenix GmbH Description and Overview
Table 135. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 136. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 137. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 138. Apogenix GmbH Recent Developments
Table 139. Bristol-Myers Squibb Company Company Information
Table 140. Bristol-Myers Squibb Company Description and Overview
Table 141. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 142. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 143. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 144. Bristol-Myers Squibb Company Recent Developments
Table 145. Five Prime Therapeutics Inc Company Information
Table 146. Five Prime Therapeutics Inc Description and Overview
Table 147. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 148. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 149. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 150. Five Prime Therapeutics Inc Recent Developments
Table 151. Incyte Corp Company Information
Table 152. Incyte Corp Description and Overview
Table 153. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 154. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 155. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 156. Incyte Corp Recent Developments
Table 157. MedImmune LLC Company Information
Table 158. MedImmune LLC Description and Overview
Table 159. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 160. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 161. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 162. MedImmune LLC Recent Developments
Table 163. Merck & Co Inc Company Information
Table 164. Merck & Co Inc Description and Overview
Table 165. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 166. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 167. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 168. Merck & Co Inc Recent Developments
Table 169. Novartis AG Company Information
Table 170. Novartis AG Description and Overview
Table 171. Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 172. Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 173. Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 174. Novartis AG Recent Developments
Table 175. OncoMed Pharmaceuticals Inc Company Information
Table 176. OncoMed Pharmaceuticals Inc Description and Overview
Table 177. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 178. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 179. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 SWOT Analysis
Table 180. OncoMed Pharmaceuticals Inc Recent Developments
Table 181. Regeneron Pharmaceuticals Inc Company Information
Table 182. Regeneron Pharmaceuticals Inc Description and Overview
Table 183. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 184. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product and Services
Table 185. Regeneron Pharmaceuticals Inc Recent Developments
Table 186. Key Raw Materials Lists
Table 187. Raw Materials Key Suppliers Lists
Table 188. Tumor Necrosis Factor Receptor Superfamily Member 18 Distributors List
Table 189. Tumor Necrosis Factor Receptor Superfamily Member 18 Customers List
Table 190. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trends
Table 191. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Drivers
Table 192. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Challenges
Table 193. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Restraints
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 18 Product Picture
Figure 2. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share by Type in 2022 & 2034
Figure 4. AMG-228 Product Picture
Figure 5. BMS-986156 Product Picture
Figure 6. FPA-154 Product Picture
Figure 7. GWN-323 Product Picture
Figure 8. INCAGN-1876 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 11. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share by Application in 2022 & 2034
Figure 12. Melanoma
Figure 13. Non-Small Cell Lung Cancer
Figure 14. Gastric Cancer
Figure 15. Blood Cancer
Figure 16. Others
Figure 17. Tumor Necrosis Factor Receptor Superfamily Member 18 Report Years Considered
Figure 18. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue 2018-2034 (US$ Million)
Figure 20. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 21. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity 2018-2034 (K Pcs)
Figure 22. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Region (2018-2024)
Figure 23. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Region (2024-2034)
Figure 24. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue YoY (2018-2034) & (US$ Million)
Figure 28. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue YoY (2018-2034) & (US$ Million)
Figure 30. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue YoY (2018-2034) & (US$ Million)
Figure 32. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 33. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue YoY (2018-2034) & (US$ Million)
Figure 34. The Top 10 and Top 5 Players Market Share by Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity in 2022
Figure 35. The Top 10 and Top 5 Players Market Share by Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue in 2022
Figure 36. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 37. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
Figure 38. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
Figure 39. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
Figure 40. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
Figure 41. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Company in 2022
Figure 42. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Company in 2022
Figure 43. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
Figure 44. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
Figure 45. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
Figure 46. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
Figure 47. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Country (2018-2034)
Figure 48. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Country (2018-2034)
Figure 49. U.S. Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 50. Canada Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 51. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Company in 2022
Figure 52. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Company in 2022
Figure 53. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
Figure 54. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
Figure 55. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
Figure 56. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
Figure 57. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Country (2018-2034)
Figure 58. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Country (2018-2034)
Figure 59. Germany Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 60. France Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 61. U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 62. Italy Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 63. Russia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 64. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Company in 2022
Figure 65. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Company in 2022
Figure 66. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
Figure 67. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
Figure 68. China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
Figure 69. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
Figure 70. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Company in 2022
Figure 71. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Company in 2022
Figure 72. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Type (2018-2034)
Figure 73. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Type (2018-2034)
Figure 74. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Application (2018-2034)
Figure 75. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share by Application (2018-2034)
Figure 76. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Region (2018-2034)
Figure 77. APAC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Share by Region (2018-2034)
Figure 78. Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 79. South Korea Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 80. China Taiwan Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 81. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 82. India Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (2018-2034) & (US$ Million)
Figure 83. Middle East, Africa and Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Quantity Market Share by Company in 2022